<abstract xmlns="http://www.w3.org/1999/xhtml">
				<bold>Background.</bold> The objective of this study is to systematically review the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) with Fluorine-18-Fluorodeoxyglucose (FDG) in patients with osteosarcoma (OS).
				<bold>Methods</bold>. A comprehensive literature search of published studies through October 10th, 2012 in PubMed/MEDLINE, Embase and Scopus databases regarding whole-body FDG-PET and FDG-PET/CT in patients with OS was performed.
				<bold>Results</bold>. We identified 13 studies including 289 patients with OS. With regard to the staging and restaging of OS, the diagnostic performance of FDG-PET and PET/CT seem to be high; FDG-PET and PET/CT seem to be superior to bone scintigraphy and conventional imaging methods in detecting bone metastases; conversely, spiral CT seems to be superior to FDG-PET in detecting pulmonary metastases from OS
				<bold>Conclusions.</bold> Metabolic imaging may provide additional information in the evaluation of OS patients. The combination of FDG-PET or FDG-PET/CT with conventional imaging methods seems to be a valuable tool in the staging and restaging of OS and may have a relevant impact on the treatment planning.
			</abstract>

Background. The objective of this study is to systematically review the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) with Fluorine-18-Fluorodeoxyglucose (FDG) in patients with osteosarcoma (OS).
				Methods. A comprehensive literature search of published studies through October 10th, 2012 in PubMed/MEDLINE, Embase and Scopus databases regarding whole-body FDG-PET and FDG-PET/CT in patients with OS was performed.
				Results. We identified 13 studies including 289 patients with OS. With regard to the staging and restaging of OS, the diagnostic performance of FDG-PET and PET/CT seem to be high; FDG-PET and PET/CT seem to be superior to bone scintigraphy and conventional imaging methods in detecting bone metastases; conversely, spiral CT seems to be superior to FDG-PET in detecting pulmonary metastases from OS
				Conclusions. Metabolic imaging may provide additional information in the evaluation of OS patients. The combination of FDG-PET or FDG-PET/CT with conventional imaging methods seems to be a valuable tool in the staging and restaging of OS and may have a relevant impact on the treatment planning.

The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma

Department of Radiological Sciences, Nuclear Medicine Unit, University of Messina, Messina, Italy

Department of Nuclear Medicine and PET/CT Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Institute of Radiology, Catholic University of the Sacred Heart, Rome, Italy

Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Rome, Italy

School of Medicine, Catholic University of the Sacred Heart, Rome, Italy

Nuclear Medicine Unit, Galliera Hospital, Genoa, Italy

Nuclear Medicine Unit, Humanitas Hospital, Milan, Italy

Positron Emission Tomography Center IRMET, Euromedic inc., Turin, Italy. Coordinator of the AIMN PET-Pediatric Study Group

Radiology and Oncology

Background. The objective of this study is to systematically review the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) with...

The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma

Online veröffentlicht: 21. Mai 2013

Seitenbereich: 97 - 183

DOI: https://doi.org/10.2478/raon-2013-0017

Schlüsselwörter
osteosarcoma, bone sarcoma, 18F-Fluorodeoxyglucose, PET/CT, positron emission tomography

This content is open access.

The role of Fluorine-18-Fluorodeoxyglucose positron emission tomography in staging and restaging of patients with osteosarcoma

Online veröffentlicht: 21. Mai 2013

Seitenbereich: 97 - 183

DOI: https://doi.org/10.2478/raon-2013-0017

Schlüsselwörterosteosarcoma, bone sarcoma, 18F-Fluorodeoxyglucose, PET/CT, positron emission tomography

This content is open access.

Schlüsselwörter
osteosarcoma, bone sarcoma, 18F-Fluorodeoxyglucose, PET/CT, positron emission tomography